19 results about "NADPH oxidase" patented technology

The present invention relates to a thiohydantoin derivative and a composition for preventing or treating NADPH oxidase (NOX)-associated diseases comprising same, and can be used to treat NADPH oxidase (NOX)-associated diseases through excellent actions on NOX inhibition.

This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid.

This invention discloses a method for delaying leaf senescence in Paspalum notatum under salt stress. The method includes the following steps: plant material culture and salt stress treatment; H2O2 content determination; DAB staining; chlorophyll content and Fv / Fm value determination; lipidomics data determination and analysis; endogenous hormone level analysis; real-time quantitative PCR analysis of gene expression levels; and transcriptomics data analysis. This invention discovers that root-derived H2O2 in Paspalum notatum under salt-driven conditions delays leaf senescence by participating in the regulation of jasmonic acid. The role of root-derived H2O2 was studied using diphenylthioiodine (DPI), a specific inhibitor of NADPH oxidase. Furthermore, the influence of the presence or absence of root-derived H2O2 on the expression of genes related to jasmonic acid synthesis precursors was investigated at the gene expression level. Mass spectrometry-based omics technology and data analysis are the first key technologies for implementing this project. Lipidomics, as one of the most important branches of metabolomics, can perform qualitative and quantitative analysis at the level of individual lipid species.

The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and / or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

This invention relates to the field of crop genetics and breeding, and discloses the sweet sorghum disease resistance gene CPK4, its encoded protein, and its applications. The nucleotide sequence of the sweet sorghum disease resistance gene CPK4 is shown in SEQ ID NO.1, or has more than 90% homology with the sequence shown in SEQ ID NO.1 and encodes a protein with a nucleotide sequence that promotes the release of reactive oxygen species (ROS) in plants. By utilizing the CPK4 gene cloned from sweet sorghum, and through the specific interaction between its encoded protein and the NADPH oxidase SbRbohD protein, the ROS signaling pathway induced by pathogens is specifically activated, strengthening the defense response of sweet sorghum against anthracnose. This achieves a targeted enhancement of sweet sorghum's resistance to anthracnose. Furthermore, this gene is specifically induced by the molecular patterns of anthracnose and pathogens, and its disease resistance mechanism differs from existing NLR-mediated immune pathways, enriching the types of sweet sorghum disease resistance gene resources.

The present invention relates to compositions and methods for treating and / or preventing heart failure with preserved ejection fraction (HFpEF), especially in subjects with an impaired NO-cGMP-PKG signalling axis. The inventors established that not all patients with clinically defined HFpEF suffer from insufficient NO-cGMP-PKG signalling. In accordance with the invention, patients with an HFpEF diagnosis can be selected / stratified based on biomarkers such as NADPH oxidase Type 5 (Nox5) plasma levels, nitration of tyrosine residues on plasma proteins and / or cell-based assays. Moreover, the inventors have found that treating this signalling network at two or more nodes, especially sGC and NO synthase, achieves the first-in-class mechanism-based, causal and high precision therapy for HFpEF endotype which is defined by insufficient NO-cGMP-PKG signalling.

The invention provides a genetic engineering modified vibrio natriureticus and an application of the genetic engineering modified vibrio natriureticus in production of xylitol. Specifically, a genetic engineering technology is utilized for the first time to introduce a heterologous gene for coding arabinose-1-dehydrogenase and a heterologous gene for coding NADPH oxidase into the vibrio natriticus, so that the modified vibrio natriticus can co-express the arabinose-1-dehydrogenase and the NADPH oxidase. Furthermore, the invention provides an application of the genetic engineering modified vibrio natriureticus disclosed by the invention in production of xylitol. L-arabinose in hemicellulose hydrolysate can be completely converted into L-arabinoic acid by utilizing the vibrio natriureticus modified by genetic engineering, so that the generation of a byproduct L-arabitol which is difficult to separate is avoided, the adverse effect of the L-arabitol is eliminated, and the production efficiency of xylitol is improved.

The present invention relates to a novel compound as an NADPH oxidase 2 inhibitor and a pharmaceutical composition containing same. More specifically, the compound according to the present invention exhibits selective and excellent inhibitory activity against NADPH oxidase 2, which is known to date, and thus can be advantageously used as a therapeutic for various diseases associated with NADPH oxidase 2, such as inflammatory diseases, fibrotic diseases, and degenerative neural diseases.

The present disclosure relates to an ionic liquid (IL)-based formulation for the treatment, therapy or prevention of a nervous system disease, in particular Parkinson's disease, said formulation comprising an inhibitor, in particular a specific inhibitor, of NADPH oxidase (Nox), preferably isoforms 1 and 4, 3-cyclohexyl-5-(2,4-dihydroxybenzylidene)-1-methyl-2-thiohydantoin.

This disclosure provides a method for alleviating aluminum toxicity in hydroponic peas based on menadione-mediated reactive oxygen species (ROS) metabolism. The core components include: regulating the concentration and duration of menadione treatment to optimize the spatiotemporal accumulation pattern of ROS (superoxide anion, hydrogen peroxide) in the roots of hydroponic peas; adjusting the dynamic response of endogenous antioxidant enzyme systems (SOD, POD, APX) to enhance menadione-mediated ROS scavenging capacity; controlling the initial ROS burst based on changes in plasma membrane NADPH oxidase (Rboh) gene expression and enzyme activity to inhibit the aluminum stress oxidative signaling cascade; and adjusting the timing and frequency of menadione administration based on subcellular-scale mitochondrial and chloroplast ROS leakage rates to alleviate organ-specific oxidative damage. This approach addresses five key issues: aluminum-induced oxidative damage, cellular redox imbalance, oxidative signaling cascade, organ-specific oxidative damage, and persistent aluminum toxicity metabolic disorders.

This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid.

Disclosed are compounds of Formula (I) below and pharmaceutically acceptable salts thereof: MNox-L-ZBG (I) in which each of variables MNox, L and ZBG is defined herein. Also disclosed is a method for treating a cancer with a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.

The present invention relates to a novel compound as an NADPH oxidase 2 inhibitor and a pharmaceutical composition containing same. More specifically, the compound according to the present invention exhibits selective and excellent inhibitory activity against NADPH oxidase 2, which is known to date, and thus can be advantageously used as a therapeutic for various diseases associated with NADPH oxidase 2, such as inflammatory diseases, fibrotic diseases, and degenerative neural diseases.

Disclosed are compounds of Formula (I) below and pharmaceutically acceptable salts thereof:in which each of variables MNox, L and ZBG is defined herein. Also disclosed is a method for treating a cancer with a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.

The invention provides a composition for inhibiting flow cytometry tandem dye degradation and application of the composition. The active ingredient of the composition is selected from the group consisting of the following components: an active oxygen scavenger represented by dihydrolipoic acid (DHLA), an NADPH oxidase inhibitor represented by VAS 2870, a superoxide dismutase (SOD) simulant having catalase activity and represented by EUK-134, and an antioxidant. The composition can further comprise auxiliary components such as an energy source, a protein stabilizer, other antioxidants, a stress protective agent and the like. The degradation rate of tandem dyes in the flow cytometry dyeing process is remarkably reduced by removing generated active oxygen or inhibiting generation of new active oxygen or under the combined action, meanwhile, the high activity of cells is kept, signal weakening of a target channel and fluorescence leakage of an adjacent channel are effectively avoided, the accuracy and repeatability of an experimental result are improved, and the method is suitable for large-scale popularization and application. The device is suitable for dyeing experiments of multicolor flow cytometry and subsequent cell sorting, culturing, sequencing and other operations.

The invention relates to the technical field of biological medicine, and particularly discloses a multi-mechanism nano-drug based on tetrahedral framework nucleic acid and application of the multi-mechanism nano-drug in acute kidney injury treatment, the nano-drug is a tFNA / GA (at) s i RNOX4 nano-composite system and is composed of the tetrahedral framework nucleic acid (tFNA), glycyrrhetinic acid (GA) and small interfering RNA (s iRNOX4) targeting NADPH oxidase 4; by adopting a single-carrier double-load strategy, effective co-delivery of the GA and the siRNOX4 is realized, the problems of poor solubility of the GA and low delivery efficiency of the si RNA are solved, and the pharmaceutical composition has definite kidney targeting property, can be massively accumulated in the kidney, especially in a renal tubule area, improves the concentration of a drug at a diseased region, and enhances the treatment effect.

Provided herein, in some embodiments, are compounds (A) that are inhibitors of NADPH oxidase (NOX) and their methods of use, for example, a method of treating a disorder such as a muscular dystrophy in a patient in need thereof, comprising administering a therapeutically effective amount of the compound.

An example of a composition for promoting metabolic health can include a combination of cyanidin and delphinidin in an amount sufficient to treat metabolic disorders.Furthermore, an example of a method for treating a condition or disorder related to metabolic health in a subject can include reducing endotoxin levels compared to baseline endotoxin levels, and adjusting cardiometabolic biomarkers related to lipid or glucose metabolism from abnormal cardiometabolic baseline levels to normal levels.Exemplary methods can also include reducing liver inflammation, treating high-fat diet-induced colon dysfunction, reducing the expression of toll-like receptors TLR4 and TLR2, reducing plasma endotoxin levels, reducing the expression of NADPH oxidase NOX1, and increasing tight junction proteins in the colon of a subject.

This invention provides the application of an S100A6 inhibitor in the preparation of a drug for treating calcium oxalate stones. This invention is the first to discover that S100A6 plays a crucial role in the formation of calcium oxalate stones. It promotes STAT3 phosphorylation, upregulates the expression of NADPH oxidase subunits p67phox and p40phox, promotes reactive oxygen species (ROS) generation, and induces autophagy and apoptosis in renal epithelial cells, thereby promoting calcium oxalate stone formation. Furthermore, the S100A6 small molecule inhibitor AP-048 provided by this invention specifically binds to S100A6. In vitro and in vivo experiments have confirmed that AP-048 can significantly inhibit calcium oxalate crystal cell adhesion, reduce ROS levels, decrease renal crystal deposition, alleviate renal tubular damage and inflammatory factor expression, and has no significant hepatotoxicity or nephrotoxicity. This invention provides a new target and therapeutic strategy for calcium oxalate stones, with promising clinical application prospects.